Ligand製藥 LGND 深 滬
等待開盤 09-06 09:30:00 美东时间
167.31
-0.430
-0.26%
華盛通- 最 高169.49
- 今 開167.86
- 成交量 12.21万股
- 最 低 166.07
- 昨 收 167.74
- 總市值 32.62亿
- 52周最高 169.49
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 93.58
- 委 比 59.40%
- 總股本 1949.45万
- 歷史最高 248.6071
- 量 比 0.83
- 振 幅 2.04%
- 歷史最低 -19.8529
- 每 手 1
- 風險率 14.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What Analysts Are Saying About Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals (NASDAQ:LGND) has been analyzed by 4 analysts in the las...
09-03 06:01
美股大行评级 | 英伟达、Snowflake、Five Below、Pure Storage等公司获多家大行集体上调目标价
今日重点评级关注：摩根大通：维持Futu Holdings"超配"评级，目标价从200美元升至270美元；Craig-Hallum：维持英伟达"买入"评级，目标价从195美元升至245美元
08-29 09:47
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $206
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $157 to $206.
08-29 00:34
Ligand to Participate in September Investor Conferences
Ligand Pharmaceuticals' CEO Todd Davis and CFO Tavo Espinoza will attend the Citi 20th Annual BioPharma Conference in Boston on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025. Management will engage in fireside chats and presentations, and host one-on-one investor meetings. Investors should contact Citi or H.C. Wainwright representatives for meeting arrangements. For more infor...
08-19 20:00
Ligand prices $400M convertible debt offering
Ligand Pharmaceuticals (NASDAQ:LGND) has priced $400 million in 0.75% convertible senior notes due 2030 in a private placement to qualified institutional buyers. Buyers have a 13-day option to purchas...
08-12 12:25
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Pharmaceuticals plans to offer $400 million in convertible senior notes due 2030 via a private placement under Rule 144A. The notes will bear interest semiannually and may be converted into cash, shares, or a combination. Proceeds will be used for general corporate purposes, including repurchasing up to $30 million in shares, financing conversions, and potential acquisitions. The company also expects to enter convertible note hedge and war...
08-11 11:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
Orchestra BioMed Holdings, Inc. announced the successful completion of strategic transactions and concurrent public and private equity offerings totaling $111.2 million in gross proceeds to support the advancement of its late-stage AVIM therapy and Virtue SAB clinical programs. The proceeds include $56.2 million from a public offering and private placements, and $55 million in royalty-based investments from Medtronic and Ligand. The funds are exp...
08-05 11:00
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
Orchestra BioMed announced it has secured $70 million in new capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. Ligand will invest $40 million, including a $15 million equity private placement, for royalties on future sales of Orchestra’s AVIM therapy and Virtue SAB. Medtronic will invest $30 million, with $10 million in equity and $20 million in a secured subordinated promissory note convertible to a...
07-31 20:01
